Letteratura scientifica selezionata sul tema "Rupture de tolérance immune"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Rupture de tolérance immune".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Rupture de tolérance immune"
Gapin, Laurent, Jean-Pierre Cabaniols, Ricardo Cibotti, Yolanda Bravo De Alba, Philippe Kourilsky e Jean Kanellopoulos. "Tolérance et rupture de tolérance". Annales de l'Institut Pasteur / Actualités 7, n. 2 (gennaio 1996): 97–118. http://dx.doi.org/10.1016/s0924-4204(97)85204-3.
Testo completoSolar cayón, José Ignacio. "Fundamentos filosóficos y jurídicos de la tolerancia religiosa en Europa (siglos XVI-XVIII) : el camino hacia la libertad". Mélanges de la Casa de Velázquez Tome 44, n. 1 (1 maggio 2014): 19–44. http://dx.doi.org/10.3917/mcv.441.0019.
Testo completoRothschild, C. "Le jeune hémophile, les inhibiteurs et la tolérance immune". Transfusion Clinique et Biologique 6, n. 3 (giugno 1999): 191–94. http://dx.doi.org/10.1016/s1246-7820(99)80024-x.
Testo completoJeandel, P. Y., E. Delmont, L. Marcq, F. Sanderson, E. Rosenthal, J. G. Fuzibet e C. Desnuelle. "Efficacité et tolérance du rituximab dans la myasthénie auto-immune". La Revue de Médecine Interne 30 (dicembre 2009): S342. http://dx.doi.org/10.1016/j.revmed.2009.10.053.
Testo completoGARCIA, C., L. BORDIER, F. BANAL, F. DUTASTA, J. V. MALFUSON e O. BERETS. "Stratégie diagnostique devant une suspicion de polyendocrinopathie auto-immune." Médecine et Armées Vol. 40 No. 2, Volume 40, Numéro 2 (1 aprile 2012): 129–34. http://dx.doi.org/10.17184/eac.6600.
Testo completoBrilland, B., C. Beauvillain, G. Mazurkiewicz, P. Rucay, J. Tabiasco, E. Vinatier, J. Riou, G. Renier, J. F. Subra e J. F. Augusto. "Rupture de tolérance et dysrégulation lymphocytaire T chez les travailleurs exposés à la silice sans atteinte pulmonaire". Néphrologie & Thérapeutique 15, n. 5 (settembre 2019): 386–87. http://dx.doi.org/10.1016/j.nephro.2019.07.299.
Testo completoLyon, J. A., J. D. Haynes, C. L. Diggs, J. D. Chulay e J. M. Pratt-Rossiter. "Plasmodium falciparum antigens synthesized by schizonts and stabilized at the merozoite surface by antibodies when schizonts mature in the presence of growth inhibitory immune serum." Journal of Immunology 136, n. 6 (15 marzo 1986): 2252–58. http://dx.doi.org/10.4049/jimmunol.136.6.2252.
Testo completoZheng, Lin-Lin, Ya-Ru Wang, Zhen-Rong Liu, Zhi-Hao Wang, Chang-Cheng Tao, Yong-Gang Xiao, Kai Zhang et al. "High spindle and kinetochore-associated complex subunit-3 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma". World Journal of Gastrointestinal Surgery 15, n. 8 (27 agosto 2023): 1600–1614. http://dx.doi.org/10.4240/wjgs.v15.i8.1600.
Testo completoNoël, E., P. Hardy, E. Laprelle, F. W. Hagena, F. Goebel e P. Goupille. "Etude prospective de la tolérance et de l'efficacité d'Hylane G-F 20 dans l'omarthrose symptomatique sans rupture de coiffe". Revue du Rhumatisme 73, n. 10-11 (novembre 2006): 1166–67. http://dx.doi.org/10.1016/j.rhum.2006.10.388.
Testo completoNoël, E., P. Hardy, F. W. Hagena, E. Laprelle, F. Goebel, C. Faure, L. Favard et al. "Efficacité et tolérance de l’Hylan GF 20 au cours de l’omarthrose sans rupture de coiffe. Étude ouverte, prospective, multicentrique". Revue du Rhumatisme 76, n. 12 (dicembre 2009): 1327–30. http://dx.doi.org/10.1016/j.rhum.2009.10.025.
Testo completoTesi sul tema "Rupture de tolérance immune"
Le, Saout Cécile. "Rupture de la tolérance périphérique en conditions de lymphopénie : coopération entre les cellules T CD8+ et CD4+". Montpellier 2, 2009. http://www.theses.fr/2009MON20097.
Testo completoThe onset of autoimmunity in patients as well as experimental rodent models frequently correlates with a lymphopenic state. In this condition, the immune system has evolved compensatory homeostatic mechanisms that induce quiescent naive T cells to proliferate and differentiate into memory-like lymphocytes even in the apparent absence of antigenic stimulation. Since memory T cells have less stringent requirements for activation than naïve cells, we hypothesized that auto-reactive T cells that arrive to secondary lymphoid organs in a lymphopenic environment could differentiate and bypass the mechanisms of peripheral tolerance. Utilizing a transgenic mouse system in which a model antigen is expressed in the pancreas, we have shown that potentially auto-reactive memory-like CD8+ T cells, generated under lymphopenic conditions, are not sufficient to induce auto-immunity because they are tolerized in the draining lymph nodes of the pancreas. Induction of self-reactivity required antigen-specific CD4+ T cell help. These helper cells promoted the further differentiation of memory-like CD8+ T cells into effectors in response to antigen cross-presentation with subsequent migration to the tissue of antigen expression where autoimmunity ensued. We also found that this effect is mediated by IL-2, a cytokine mainly produced by CD4 helper T cells. Thus, the cooperation between self-reactive memory-like CD4+ and CD8+ T cells under lymphopenic conditions overcomes cross-tolerance resulting in autoimmunity. These studies raise new perspectives, notably on cancer immunotherapy and the development of promising strategies optimizing anti-tumor T cell responses
Guffroy, Aurélien. "Etude des mécanismes de rupture de tolérance lymphocytaire au cours des déficits immunitaires primitifs de l'adulte avec manifesations auto-immunes". Thesis, Strasbourg, 2019. http://www.theses.fr/2019STRAJ012.
Testo completoThe association between primary immune deficiency (PID) and autoimmunity may seem paradoxical when PID is considered only as an immune response defect against pathogens and autoimmunity only as an excess of immunity. Nevertheless, far from being simple immune defects increasing the risk of infections, DIPs are frequently associated with autoimmunity. Even more, autoimmunes manifestations can sometimes reveal a PID. Thus, epidemiological data from registers or large series of patients with PIDs agree on an overall prevalence of 25 to 30% of autoimmune complications (with auto-immune cytopenias as first causes). Several hypotheses have been proposed with different underlying mechanisms to explain the tolerance breakdown in PIDs. We can cite : 1°) a severe disturbance of lymphocyte homeostasis, for example in severe combined immunodeficiencies ; 2°) an impaired B-cell developpement with earlystage defects of tolerance ; 3°) a dysregulation of T cells (developpement or activation impairments) ; 4°) a dysfunction of T-reg (or B-reg) ; 5°) an excess of production of proinflammatory cytokines. These hypotheses are especially true for early-onset PIDs (in infancy). In this work (PhD), we explore the mechanisms of tolerance breakdown involved in adults PIDs. We use several approaches to describe the pathways leading to autoimmunity, focusing on the most common PID in adult : CVID (common variable immunodeficiency). This syndrome is not well defined on the genetic and physiopathological level. It is still a therapeutic challenge when complicated by autoimmunity (requiring immunosuppressive therapy)
Peter, Elise. "Mécanismes immunopathologiques des dégénérescences cérébelleuses paranéoplasiques". Electronic Thesis or Diss., Lyon 1, 2024. http://www.theses.fr/2024LYO10329.
Testo completoBackground: Paraneoplastic cerebellar degeneration (PCD) are rare autoimmune disorders affecting an otherwise immune-privileged site: the central nervous system. This autoimmunity is associated with the presence of a cancer and is satellite of the anti-tumor immune response, the B-cell response originating a secretion of autoantibodies that are diagnostic hallmarks of these disorders. These autoantibodies are directed against a protein expressed both in the tumor and in the CNS, the so-called onconeural antigen. The triggers of the immune tolerance breakdown and the exact relationship between the tumor, the immune system and the neurological symptoms are still not totally understood. Recent studies have allowed to show that in some tumors associated with paraneoplastic syndromes (namely ovarian and breast cancers associated with Yo syndrome), the onconeural antigen is overexpressed due to the presence of a gain or amplification in the gene locus and may present mutations while in others, none of these alterations of the onconeural antigen are present (e.g. lung cancers in Hu syndrome). The objectives of this thesis work are to further analyze the link between the tumor and the paraneoplastic autoimmunity by comparing two syndromes associated with the same type of cancer (Ri and Yo syndrome associated with breast cancers, RGS8 and DNER syndrome associated with Hodgkin’s lymphoma) and to search for antigen alterations in another syndrome (Ri syndrome).Methods: we conducted two studies within the frame of this thesis work. A first study on a clinical and pathological cohort of breast cancers associated with Ri-syndrome using clinicopathological data, DNA-sequencing, and whole-transcriptome analysis. A second analysis on three patients with RGS8-syndrome using clinicopathological data and Phage Immunoprecipitation sequencing (PhIP-seq).Results: Ri breast cancers were a subtype different than one observed in Yo with uncommon genetic features that singularize them among their subtype. Neither overexpression nor genetic alteration of the Ri onconeural antigens were found in Ri breast cancers. Conversely, the anti-tumor immune reaction in Ri breast cancers was similar to the one found in Yo: an atypical intratumoral B-cell infiltration.Concerning RGS8 paraneoplastic cerebellar degeneration, two patients presented with a Hodgkin lymphoma of the rare specific subtype called nodular lymphocyte-predominant Hodgkin lymphoma, whereas DNER is associated with the classical nodular-sclerosing form. Autoantibodies detected in all patients enriched the same epitope on the RGS8 protein, which is an intracellular protein physiologically expressed in Purkinje cells but also ectopically expressed specifically in lymphoma cells of patients with RGS8-syndrome.Conclusion: each paraneoplastic syndrome is associated with a specific histomolecular subtype of cancer with uncommon genetic features, which provides the first evidence of a tight link between oncogenesis and paraneoplastic immunity. Alterations of the antigen (overexpression, copy number variation and mutation) may be the mechanism of immune tolerance breakdown in several different syndromes but are not ubiquitous. The antitumor immunity seems to be an atypical B-cell response in several subtypes irrespective of the tumor type and antigen alterations. These results are a step forward in our understanding of paraneoplastic immunity and provide clues on potential predictive markers of paraneoplastic immunity that may be of use in personalizing medical decision of immunotherapy in the field of oncology
Villagrán-García, Macarena. "Clinical-immunological characterization and immune tolerance breakdown in paraneoplastic neurological syndromes associated with Hu antibodies". Electronic Thesis or Diss., Lyon 1, 2024. http://www.theses.fr/2024LYO10259.
Testo completoHu antibodies, the most common in paraneoplastic neurological syndromes (PNS), strongly indicate small-cell lung cancer (SCLC). The clinical spectrum of Hu-PNS is diverse, most patients develop multifocal central, peripheral, and/or autonomic nervous system dysfunction. Despite extensive research, questions remain, namely regarding the immunological basis of clinical heterogeneity and why only a minority of SCLC patients develop Hu-PNS. Our PhD project aims to phenotype Hu-PNS patients, explore the immunogenetics and humoral responses underlying neurological phenotypes, and the genomic and transcriptomic features of their SCLC. First, we described 466 Hu-PNS patients. Hierarchical clustering identified three groups: patients with central nervous system (CNS) involvement; isolated neuropathy; and mixed CNS/peripheral phenotypes. Overall survival was similar across groups, primarily determined by cancer, but dysautonomia, present in 26% of patients, significantly influenced neurological mortality. Prominent CNS dysfunction led to fatal cardiovascular dysautonomia or central hypoventilation, while peripheral involvement was associated with gastrointestinal or secretomotor alterations, without increased mortality risk. We also characterized patients who developed neurological syndromes with Hu antibodies after immune checkpoint inhibitor (ICI) treatment. These patients were clinically indistinguishable from spontaneous cases and shared a strong association with SCLC, suggesting ICIs may induce Hu-PNS. Second, we immunologically investigated neurological phenotypes using two approaches. HLA genotyping of 100 patients confirmed an association with the DR3~DQ2 haplotype, particularly in patients with sensory neuropathy, and absent in those with only CNS involvement. Phage immunoprecipitation sequencing was used to evaluate Hu antibody epitope reactivity and other autoantibodies in serum and/or CSF of 210 patients. We found no direct clinical association with the Hu dominant epitope, but epitope reactivity differed between serum and CSF in 75% of patients with paired samples. This variation correlated with sample timing and phenotype: CSF from patients with differing serum/CSF epitopes was collected later after PNS onset, while patients with serum/CSF consistent epitope reactivity always had CNS phenotypes. In addition, we identified reactivities to other proteins, some more specific to serum or CSF, and a subset linked to specific phenotypes. Third, we examined SCLC molecular features of Hu-, GABAbR-PNS and control patients. Next-generation sequencing, copy number variation analysis, and bulk-RNA sequencing revealed no mutations, gains, deletions, or overexpression in the Hu gene family of Hu-PNS SCLC. However, a distinct transcriptomic profile with upregulated genes largely related to immune system processes characterized these tumors. We also identified specific genes upregulated in the SCLC of patients with sensory neuropathy, some of which were linked to axonogenesis and neuropathy development. Our findings suggest multiple factors contribute to Hu-PNS clinical variability, particularly a broad range of additional autoantigens. These may be partly driven by gene expression patterns in SCLC, as some upregulated genes in patients with sensory neuropathy were linked to axonogenesis. Genetic predisposition may also favor specific phenotypes, as the DR3~DQ2 haplotype was associated with sensory neuropathy. Compartmentalization within the nervous system could further contribute, as most patients targeted different Hu epitopes in serum and CSF, and some autoantigens were more specific to CSF. Finally, Hu genes alterations in SCLC are unlikely causes of neoantigenicity, while a distinct immune-related gene profile and ICIs could contribute to immune tolerance breakdown. This work advances understanding of Hu-PNS complexity and paves the way for further studies into the immunological and molecular drivers of paraneoplastic immunity
Soulas-Sprauel, Pauline. "Autoréactivité B lymphocytaire : de la tolérance à sa rupture". Université Louis Pasteur (Strasbourg) (1971-2008), 2003. http://www.theses.fr/2003STR1A002.
Testo completoIn most transgenic (tg) murine models expressing an autoantibody on B cells, the autoreactive B cells are eliminated physically or functionally. These data do not account for clinical observations made in humans, specially concerning Rheumatoi͏̈d Factors (RF, autoantibody against Fc portion of IgG) : high frequency of RF producing B cells in normal individuals and tolerance breakdown in some pathological situations. To understand this paradox, we produced tg mice expressing IgM only, or IgM/IgD chimeric RFs (human variable regions, murine constant regions) : Smi, a natural polyreactive low affinity RF, and Hul, a monoreactive high affinity RF. Analysis of B cell tolerance in these tg models show that : 1) Smi RF B cells are not deleted after antigen peripheral encounter. 2) IgM-only Hul RF B cells are deleted after peripheral encounter with human IgG (hIgG), but IgM/IgD mature B cells are protected from deletion. 3) Smi RF B cells are positively selected by constitutive expression of chimeric cIgG with human Fcg. 4) Smi and Hul RF B cells are in a state of immunological ignorance. These data reproduce the physiological situation. We next studied the role of inhibitory receptor FcgRIIB in maintaining this state of immunological ignorance. Hul FcgRIIB-/- RF B cells are activated by hIgG in vitro but hIgG injection in Hul FcgRIIB-/- mice doesn't induce a production of RF. We can therefore assume that FcgRIIB is not the preferential mechanism which maintain Hul RF B cell tolerance. Could an infectious disease break B cell tolerance ? We infected RF Smi and Hul tg mice, with or without autoantigen cIgG expression, with Borrelia burgdorferi. FR Smi and Hul tg mice infection induce a tolerance breakdown, with FR production, specific for autoantigen. These data could explain the association between infection and autoimmune diseases
Condamine, Thomas. "Caractérisation de nouvelles molécules impliquées dans la tolérance immune". Nantes, 2009. https://archive.bu.univ-nantes.fr/pollux/show/show?id=7ae11d03-0c92-4e1e-a1a5-0c1a174b07a0.
Testo completoA better understanding of immune mechanisms involved in allograft rejection or tolerance has to be considered as a major research goal. This knowledge could lead to the design of new therapeutical approach that could be used in the future to replace immunosuppressive treatment. In the first part of this thesis, we have study the potential role of two molecules upregulated in a model of cardiac allograft tolerance in the rat: The Follistatin-Like 1 (FSTL1) and TORID. We have shown that FSTL1 is produced by graft infiltrating CD8+ T cells in this model and that FSTL1 could induce a prolonged allograft survival in association with inhibition of the proinflammatory cytokines, IL6, IL17 and IFNγ. In the study of the molecule TORID, we have been able to show a role of this molecule in the maturation of dendritic cells (DC) and a role on the regulation, of previously described, immunomodulatory enzymes in myeloid derived suppressor cells (MDSC). In addition, in a model of skin graft tolerance induction involving MDSC, we have shown that we can not induce a tolerance in TORID deficient mice. In the second part of this thesis, we have study the expression and regulation of the molecule Schlafen-3 (SLFN3) in the immune system and in particular in regulatory T cells (Tregs). We have been able to show that this molecules was strongly expressed in Tregs in comparison to effectors T cells and that, following stimulation, the expression of SLFN3 is downregulated in Tregs but increased in effectors T cells
Halbout, Philippe. "Rôle de l'insuline dans la rupture de tolérance chez la souris NOD". Paris 6, 2002. http://www.theses.fr/2002PA066173.
Testo completoDiet, Stéphane. "Mécanismes de rupture des côtes et critères de tolérance thoracique en choc automobile". Phd thesis, Ecole nationale supérieure d'arts et métiers - ENSAM, 2005. http://pastel.archives-ouvertes.fr/pastel-00568920.
Testo completoYaacoub, Agha Hassan. "Tolérance aux défauts initiaux : application à une fonte G.S. en fatigue". Paris 6, 1996. http://www.theses.fr/1996PA066828.
Testo completoWoods, Anne. "Infection et autoimmunité : Approches expérimentale des mécanismes de rupture de la tolérance B lymphocytaire". Université Louis Pasteur (Strasbourg) (1971-2008), 2007. https://publication-theses.unistra.fr/public/theses_doctorat/2007/WOODS_Anne_2007.pdf.
Testo completoAutoimmune diseases are associated with genetic and environmental factors. Among the latter, infections have been particularly implicated. However, the mecanisms of such an association between infections and autoimmune diseases are still unknown. We have tried to understand those mecanisms by using transgenic mouse models expressing chimeric rheumatoid factors (RF) in the presence or in the absence of their autoantigen (human IgG). In these models, RF B cells are ignorant towards their autoantigen. However, infection of RF trangenic mice with Borrelia burgdorferi (Bb) breaks this state of tolerance thanks to the formation of Bb/anti-Bb human IgG immune complexes that induce a synergic signal between the BCR and a receptor recognising Bb antigens (probably a Toll-like receptor, TLR). This tolerance breakdown needs T cell help. On the other hand, infection with influenza virus does not break RF B cell tolerance in our tg model although this infection is able to induce type I IFN production, otherwise often associated with autoimmune diseases, and even when the transgene is expressend on an autoimmune background, NZBxNZW(F1). Bb infection induces a polyclonal B cell activation. Ce phenomenon is not well known, it has consequences on the immune response against infections and on the production of potentially harmfull autoantibodies. The infection of MyD88 deficient mice (considered at first to understand the role of TLR in the RF B cell tolerance breakdown) showed that this protein is important for polyclonal B cell activation. MyD88 inhibits the development of a Th2 immune response, thus probably preventing an increased production of IL-4 that can directly and excessively activate B cells
Libri sul tema "Rupture de tolérance immune"
1922-, Good Robert A., e Lindenlaub E, a cura di. The Nature, cellular, and biochemical basis and management of immunodeficiencies: Symposium Bernried, West Germany, 21st - 25th September, 1986. Stuttgart: F.K. Schattauer Verlag, 1987.
Cerca il testo completoed, Gonzalez Norberto C., e Lindenlaub E. ed, a cura di. The Nature, cellular, and biochemical basis and management of immunodeficiencies: Symposium Bernried, West Germany, 21st - 25th September, 1986. Stuttgart: F.K. Schattauer Verlag, 1987.
Cerca il testo completo(Editor), Elke Lindenlaub, a cura di. The Nature, Cellular, and Biochemical Basis and Management of Immunodeficiencies (Symposia Medica Hoechst, No 21). Wiley-Liss, 1988.
Cerca il testo completoCapitoli di libri sul tema "Rupture de tolérance immune"
Lee, R. T., e P. Libby. "Metalloproteinases and Atherosclerotic Plaque Rupture". In The Role of Immune Mechanisms in Cardiovascular Disease, 238–46. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60463-8_21.
Testo completoCarroll, Brian. "Symbolic Rupture". In The Circus Is in Town, 119–41. University Press of Mississippi, 2022. http://dx.doi.org/10.14325/mississippi/9781496836502.003.0005.
Testo completoSwirsky, D. "The spleen and its disorders". In Oxford Textbook of Medicine, 4334–42. Oxford University Press, 2010. http://dx.doi.org/10.1093/med/9780199204854.003.220404.
Testo completoRose, Marika. "Conclusion: Theology as Failure". In A Theology of Failure, 175–82. Fordham University Press, 2019. http://dx.doi.org/10.5422/fordham/9780823284078.003.0008.
Testo completoMatyas, Melinda. "Preterm Birth and Inflammation". In Caesarean Section [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96970.
Testo completoGoel, Ms Neha. "Basic Mechanism Involved in the Process of Inflammation and Repair-II". In Edited Book of Pathophysiology, 45–62. Iterative International Publishers, Selfypage Developers Pvt Ltd, 2024. http://dx.doi.org/10.58532/nbennurebch4.
Testo completoAtti di convegni sul tema "Rupture de tolérance immune"
Antonios, J., T. Barak, B. Gultekin, K. Yalcin, A. Chamberlain, R. Hebert, C. Matouk e M. Gunel. "O-068 Regulatory B cell and adjunctive immune population drives intracranial aneurysm rupture in patient population". In SNIS 20th Annual Meeting Abstracts. BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd., 2023. http://dx.doi.org/10.1136/jnis-2023-snis.68.
Testo completo